Anti-alpha-gal antibody response following xenogeneic heart valve implantation in adults

Journal of Heart Valve Disease

Volumn 22, Issue 2, 2013, Pages 222-229

  Park, Chun Soo ^a   Oh, Sam Se ^b   Kim, Young Eun ^c   Choi, Sun Young ^d   Lim, Hong Gook ^c   Ahn, Hyuk ^c   Kim, Yong Jin ^c,d  

^a University of Ulsan   (South Korea)

^b Sejong General Hospital   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

A GAL ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; UNCLASSIFIED DRUG; ALPHA GALACTOSYL EPITOPE; ALPHA-GALACTOSYL EPITOPE; HETEROPHILE ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; TRISACCHARIDE;

AGED; ANTIBODY RESPONSE; ARTICLE; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEART SURGERY; HEART VALVE REPLACEMENT; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MECHANICAL HEART VALVE; PRIORITY JOURNAL; SURVIVOR; ADULT; BIOPROSTHESIS; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART VALVE PROSTHESIS; IMMUNOLOGY; MIDDLE AGED; TIME;

ADULT; AGED; ANTIBODIES, HETEROPHILE; BIOPROSTHESIS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; TIME FACTORS; TRISACCHARIDES;

MLCS; MLOWN;

EID: 84880528243     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: Progress toward understanding and prevention. Ann Thorac Surg 2005;79:1072-1080
2. David TE, Armstrong S, Maganti M. Hancock II bioprosthesis for aortic valve replacement: The gold standard of bioprosthetic valves durability? Ann Thorac Surg 2010;90:775-781
3. McClure RS, Narayanasamy N, Wiegerinck E, et al. Late outcomes for aortic valve replacement with the Carpentier-Edwards pericardial bioprosthesis: Up to 17-year follow-up in 1, 000 patients. Ann Thorac Surg 2010;89:1410-1416
4. Myken PS, Bech-Hansen O. A 20-year experience of 1712 patients with the Biocor porcine bioprosthesis. J Thorac Cardiovasc Surg 2009;137:76-81
5. Stassano P, Di Tommaso L, Monaco M, et al. Aortic valve replacement: A prospective randomized evaluation of mechanical versus biological valves in patients ages 55 to 70 years. J Am Coll Cardiol 2009;54:1862-1868
6. Weber A, Noureddine H, Englberger L, et al. Tenyear comparison of pericardial tissue valves versus mechanical prostheses for aortic valve replacement in patients younger than 60 years of age. J Thorac Cardiovasc Surg 2012;144:1075-1083
7. Simionescu DT. Prevention of calcification in bioprosthetic heart valves: Challenges and perspectives. Expert Opin Biol Ther 2004;4:1971-1985
8. Galili U. The alpha-gal epitope (Gal alpha l-3Gal beta l-4GlcNAc-R) in xenotransplantation. Biochimie 2001;83:557-563
9. Bracy JL, Cretin N, Cooper DK, Iacomini J. Xenoreactive natural antibodies. Cell Mol Life Sci 1999;56:1001-1007
10. l0. Kasimir MT, Rieder E, Seebacher G, Wolner E, Weigel G, Simon P. Presence and elimination of the xenoantigen gal (alphal, 3) gal in tissue-engineered heart valves. Tissue Eng 2005;11:1274-1280
11. Konakci KZ, Bohle B, Blumer R, et al. Alpha-Gal on bioprostheses: Xenograft immune response in cardiac surgery. Eur J Clin Invest 2005;35:17-23
12. Human P, Zilla P. Characterization of the immune response to valve bioprostheses and its role in primary tissue failure. Ann Thorac Surg 2001;71(5 Suppl.):S385-S388
13. Manji RA, Zhu LF, Nijjar NK, et al. Glutaraldehydefixed bioprosthetic heart valve conduits calcify and fail from xenograft rejection. Circulation 2006;114:318-327
14. McGregor CG, Carpentier A, Lila N, Logan JS, Byrne GW. Cardiac xenotransplantation technology provides materials for improved bioprosthetic heart valves. J Thorac Cardiovasc Surg 2011;141:269-275
15. Park CS, Park SS, Choi SY, Yoon SH, Kim WH, Kim YJ. Anti alpha-gal immune response following porcine bioprosthesis implantation in children. J Heart Valve Dis 2010;19:124-130
16. Mangold A, Szerafin T, Hoetzenecker K, et al. Alpha-Gal specific IgG immune response after implantation of bioprostheses. Thorac Cardiovasc Surg 2009;57:191-195
17. Mathapati S, Verma RS, Cherian KM, Guhathakurta S. Inflammatory responses of tissue-engineered xenografts in a clinical scenario. Interact Cardiovasc Thorac Surg 2011;12:360-365
18. van Velzen-Blad H, Dijkstra YJ, Schurink GA, et al. Cardiopulmonary bypass and host defense functions in human beings: I. Serum levels and role of immunoglobulins and complement in phagocytosis. Ann Thorac Surg 1985;39:207-211
19. Lante W, Franke A, Weinhold C, Markewitz A. Immunoglobulin levels and lymphocyte subsets following cardiac operations: Further evidence for a T-helper cell shifting. Thorac Cardiovasc Surg 2005;53:16-22
20. Dau PC. Immunologic rebound. J Clin Apher 1995;10:210-217
21. Stavnezer J. Immunoglobulin class switching. Curr Opin Immunol 1996;8:199-205
22. Buonomano R, Tinguely C, Rieben R, Mohacsi PJ, Nydegger UE. Quantitation and characterization of anti-Galalphal-3Gal antibodies in sera of 200 healthy persons. Xenotransplantation 1999;6:173-180
23. McMorrow IM, Comrack CA, Nazarey PP, Sachs DH, der Simonian H. Relationship between ABO blood group and levels of Gal alpha, 3Galactose-reactive human immunoglobulin G. Transplantation 1997;64:546-549
24. Stone KR, Abdel-Motal UM, Walgenbach AW, Turek TJ, Galili U. Replacement of human anterior cruciate ligaments with pig ligaments: A model for anti-non-gal antibody response in long-term xenotransplantation. Transplantation 2007;83:211-219
25. Baumann BC, Stussi G, Huggel K, Rieben R, Seebach JD. Reactivity of human natural antibodies to endothelial cells from Galalpha (1, 3) Gal-deficient pigs. Transplantation 2007;83:193-201
26. Zhu A, Hurst R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 2002;9:376-381